drugset / Trial / NCT00552240

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

NCT00552240 ↗

Phase 4 Completed 154 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).

Timeline

Start
2007-09
Primary completion
2010-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg —
Comparator Nevirapine Small molecule 200 mg —
Comparator Ritonavir Other / unclassified 100 mg —
Comparator Tenofovir disoproxil fumarate Small molecule 300 mg —
Comparator emtricitabine Other / unclassified 200 mg —